The site is secure. The ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
If a sleeping Pokémon with Insomnia is sent into battle as one of the lead Pokémon or to replace a fainted Pokémon, or gains Insomnia due to Trace, it will not be cured of sleep until after a Pokémon takes its turn (uses a move, switches out, etc.). It will be cured of sleep if it is switched in to replace a switched out Pokémon (including if switched in via Baton Pass).
Moe cure net walkthrough
If a sleeping Pokémon has Insomnia as its original Ability but not its current Ability, if it is one of the active Pokémon at the end of the battle or switched out, it will be cured of sleep (with no message).
The Vault 81 cure is the only cure for the mole rat disease contracted after being bitten by a Vault 81 lab mole rat. There is only one dose given to the player character by Curie and one has to decide if they want to give it to Austin or keep it for themselves in the case they have contracted the disease.
I also wanted to ask if I should apply the dousing rule to Nitrates. my test goes straight from 0 to 5 for Nitrates . Do I douse with prime just as I would for Nitrates and ammonia? Or is removing water the only cure for nitrates?
Dr. Mario 64 features a story behind the gameplay. During a flu outbreak, Dr. Mario attempts to use his Megavitamins to heal the citizens. Wario, however, wishes to steal and profit from the Megavitamins. Mad Scienstein intervenes and takes the Megavitamins, so after Dr. Mario beats Wario, the two follow Mad Scienstein, defeating enemies from Wario Land 3. Mad Scienstein then reveals himself to be a worker for Rudy, who is afflicted with the cold. Dr. Mario proceeds to cure Rudy after beating him, though. If Dr. Mario has not lost any matches, however, Wario takes the Megavitamins and transforms into Vampire Wario. On the other hand, if the player is using Wario, Dr. Mario becomes Metal Mario after ingesting the pills.
Mario responds by setting out to find all four Music Keys, along with Toad. Using his SS Brass to navigate, Mario challenges the key owners to dance-offs. After Mario wins the keys, however, Bowser steals them. Mario performs the "Final Dance Off" with him and gets the Music Keys back. Bowser reveals his intentions of stealing the keys: to help cure his tone-deafness. Mario and Toad decide to use the keys to change Bowser's Castle and the surrounding area into a paradise. From this, though, some music has been implemented into their souls, so they cannot stop dancing. These keys then are all returned to the Truffle Towers.
Welcome to Part II of what is arguably the best video game ever made. (FFIX and FFIV are also very strong contenders for the honor.) I think everything that needed to be said has already been said, so . . . . on to the walkthrough.
Once they croak, a door will appear, and you can enter the depths of Owzer's basement, a dark and gloomy area. Most of the paintings here are possessed; there's one of Maria in which her figure turns around and around (which confused the hell out of me the first time I played the game.) Another of an old woman will attack you almost as soon as you enter the basement. Walk behind the wall with 3 doors to find an interesting Relic, the Relic Ring (walk as far as you can to the left, then press X/A.) This thing reverses some spell effects; it makes Doom and Poison cure the character equipped with it, while Cure or Life will injure. (Kinda like making them undead, but not really.) Go through the door farthest to the left. You can stand beneath the floating chests to fight an enemy and receive an item. Investigate the picture of the armor. Then head through the door. Save your game and go through the RIGHT-hand door, as the left dumps you right back at the beginning. Fight Chadarnook.
Ice DragonHP: 24,400Weakness: FireWell, gee, I wonder how I should fight this battle? Uhhhh . . . . Come on, if you can't figure this one out, not even this walkthrough will get you through the game . . . Strategy #1: The same one I give for every boss. Smack the bastard with Vanish/Doom. Strategy #2: Keep hitting him with Fire2; summon Ifrit or Bahamut; cast Flare if you have it. Equip someone with the Flame Sabre and have them fight. Have Shadow throw Fire Skeans; have anyone use a Fire Rod as an Item. Equip Strago with a Fire Rod, or use his Revenge Lore (only if his HP is running very low.) Don't have Relm Sketch, and Control doesn't work with a boss; just have her cast Fire, equip a Fire Rod and fight, or act as a healer. Sabin should use his FireDance (duh) or his Bum Rush Blitzes. Edgar can either attack with a fire-elemental weapon or cast Fire spells. Celes's Runic really won't be helpful if everyone else is throwing magic around; have her cast Fire spells or act as a healer. Mog can fight or cast Fire. None of the dragons are particularly tough, and this one is no exception. Once it's dead, if Mog is in your party, fight another enemy in the area to gain his Snowman Jazz dance. Now head up to where the Tritoch Esper is hanging out. You must fight this Esper to gain its Magicite.
L.10 Magic: Weak against Fire.L.20 Magic: HAS REFLECT; weak against Bolt.L.30 Magic: CAN CAST REFLECT; weak against Ice and PoisonL.40 Magic: Weak against BoltL.50 Magic: Weak against Fire; absorbs Poison.L.60 Magic: Weak against Fire; can cast Quake.L.70 Magic: HAS REFLECT; weak against Ice; absorbs FireL.80 Magic: Weak against Fire. These ladies tend to cast Cure spells on you, which bounce off your Reflect and cure them. To get rid of them quickly, just cast Doom.L.90 Magic: HAS REFLECT; weak against Bolt. Use Siren IMMEDIATELY on these; they can cast Merton, which passes right through Reflect.
Congratulations! You've just finished the most awesome RPG ever made. Enjoy the ending; you earned it. (And if you want, you can check out a fanfic I am writing with a friend, which is our version of what happens after this battle.) If you've got Anthology, you can now view the complete Bonus Mode. If you've got questions or comments about anything in this walkthrough, please email me (rina@rpgplace.net).
To prevent recurrence among HSCT candidates with parasitologically confirmed strongyloidiasis, cure after therapy should be verified with >3 consecutive negative stool examinations before proceeding with HSCT (AIII). Data are insufficient to recommend a drug prophylaxis regimen after HSCT to prevent recurrence of strongyloidiasis. HSCT recipients who had strongyloidiasis before or after HSCT should be monitored carefully for signs and symptoms of recurrent infection for 6 months after treatment (BIII).
The medical history of the prospective HSCT donor should include the following: History of vaccinations (377) during the 4 weeks before donation (AII). If the potential donor is unsure of vaccinations received, his or her records should be reviewed. HSCT donation should be deferred for 4 weeks after the donor receives any live-attenuated vaccine (e.g., rubeola [measles], mumps, rubella [German measles], oral polio, varicella, yellow fever, and oral typhoid vaccines) (EIII). This deferral will avoid the possibility of infusing a live infectious agent into an HSCT recipient. HSCT donation need not be deferred for persons who have recently received toxoid or killed (i.e., inactivated), recombinant viral, bacterial, or rickettsial vaccines as long as the donor is asymptomatic and afebrile (389) (BIII). Such vaccines include tetanus toxoid, diphtheria toxoid, hepatitis A and B, cholera, influenza (i.e., killed intramuscular vaccine), meningococcal, paratyphoid, pertussis, plague, polio (i.e., inactivated polio vaccine), rabies, typhoid (i.e., inactivated intramuscular vaccine), or typhus vaccines (389). Travel history (BIII) to determine whether the donor has ever resided in or traveled to countries with endemic diseases that might be transmitted through HSCT (e.g., malaria). Permanent residents of nonendemic countries who have traveled to an area that CDC regards as endemic for malaria can be accepted as HSCT donors if 1 year has elapsed since the donor's departure from the endemic area and if the donor has been free of malaria symptoms, regardless of whether he or she received antimalarial chemoprophylaxis. Because cases of HSCT-transmitted malaria have been reported (391,392), persons who have had malaria and received appropriate treatment should be deferred from HSCT donation for 3 years after becoming asymptomatic. Immigrants, refugees, citizens, or residents for >5 years of endemic countries can be accepted as HSCT donors if 3 years have elapsed since they departed the malarious area and if they have been free of malaria symptoms. History of Chagas' disease and leishmaniasis. Persons with active Chagas' disease or leishmaniasis should not serve as HSCT donors (DIII) because these diseases can be transmitted by transfusion (227,229,231,393--395). Researchers also recommend deferral of HSCT donation if a past history exists of either of these diseases because the parasite can persist despite therapy (227--229,231, 389,393--395) (CIII). History of any deferral from plasma or blood donation. The reason for such a deferral (376) and whether it was based on a reported infectious disease or behavioral or other risk factor should be investigated (BIII). History of viral hepatitis. A person with a history of viral hepatitis after his or her eleventh birthday should be excluded from HSCT donation (BIII). History of blood product transfusion, solid organ transplantation, or transplantation of tissue within the last 12 months (BIII). Such persons should be excluded from HSCT donation (DIII). Xenotransplant product recipients and their close contacts should be indefinitely deferred from donating any blood products, including hematopoietic stem cells, whole blood, or other blood components including plasma, leukocytes, and tissues (396) (AIII). Close contacts to be deferred from donations include persons who have engaged repeatedly in activities that could result in an intimate exchange of body fluids with a xenotransplantation product recipient. Such close contacts could include sexual partners, household members who share razors or toothbrushes, and HCWs or laboratory personnel with repeated percutaneous, mucosal, or other direct exposures. History of risk factors for classic Creutzfeldt-Jakob disease (CJD), including any blood relative with Creutzfeldt-Jakob disease, receipt of a human pituitary-derived growth hormone or receipt of a corneal or dura mater graft (383,397--399) (BIII). Potential HSCT donors should also be screened for new variant Creutzfeldt-Jakob Disease (nvCJD) risk factors, including a history of cumulative travel or residence in the United Kingdom for >6 months during 1980--1996 or receipt of injectable bovine insulin since 1980, unless the product was not manufactured since 1980 from cattle in the United Kingdom (398) (BIII). The clinical latency period for iatrogenic, classic CJD can be >30 years (398), and transmission of classic CJD by blood products is highly unlikely (398). Although no classic or nvCJD has ever been reported among HSCT recipients, persons with a history of classic or nvCJD risk factors should be excluded from donation for unrelated HSCT (DIII) if a choice exists between two otherwise equally suitable donors. The risk for transmitting classic or nvCJD from an HSCT donor to a recipient is unknown, but researchers believe that persons with nvCJD risk factors could be at higher risk for transmitting nvCJD to HSCT recipients than persons with classic CJD risk factors. Past medical history that indicates the donor has clinical evidence of or is at high risk for acquiring a bloodborne infection (e.g., HIV-1 or -2, human T-lymphotropic virus [HTLV]-I or -II, hepatitis C, or hepatitis B) (381,383), including men who have had sex with another man during the preceding 5 years (381,383) (BIII);
persons who report nonmedical intravenous, intramuscular, or subcutaneous injection of drugs during the preceding 5 years (381) (BIII);
persons with hemophilia or related clotting disorders who have received human-derived clotting factor concentrates (381) (BIII);
persons who have engaged in sex in exchange for money or drugs during the preceding 5 years (381) (BIII);
persons who have had sex during the preceding 12 months with any person described previously (381) or with a person known or suspected to have HIV (381) or hepatitis B infections (BIII);
persons who have been exposed during the preceding 12 months to known or suspected HIV, hepatitis B- or C-infected blood through percutaneous inoculation or through contact with an open wound, nonintact skin, or mucous membrane (381) (BIII);
inmates of correctional systems (379--381) and persons who have been incarcerated for >72 consecutive hours during the previous 12 months (BIII);
persons who have had or have been treated for syphilis or gonorrhea during the preceding 12 months (376,379,380) (BIII); and
persons who within 12 months have undergone tattooing, acupuncture, ear or body piercing (380,400,401) in which shared instruments are known to have been used (BIII) or other nonsterile conditions existed.
Persons reporting any of these past medical histories should be excluded from donation (DIII).The following serologic tests should be performed for each prospective donor: HIV-1 antigen, anti-HIV-1 and -2, anti-HTLV-I and -II, hepatitis B surface antigen, total antihepatitis B core antigen, antihepatitis C, anti-CMV, and a serologic test for syphilis (376,379,380,383) (AIII). Potential donors who have repeatedly reactive screening tests for HIV-1 antigen, anti-HIV-1 or -2, anti-HTLV-I or -II, antihepatitis C, hepatitis B surface antigen, or antihepatitis B core antigen should be excluded as HSCT donors (381) (EII). Persons who refuse infectious disease testing should also be excluded as HSCT donors (381) (EIII). Investigational nucleic acid tests to detect hepatitis C virus RNA and HIV RNA are currently being used in the United States to screen blood donors and could be used for screening HSCT donors. If nucleic acid tests are approved by FDA, these tests should be incorporated into routine screening regimens for HSCT donors. When nucleic acid testing is done for HIV and hepatitis C investigationally, a positive result should exclude the potential donor.All infectious disease testing and results should be reported to the HSCT physician before the candidate's conditioning regimen begins (381) (AIII). Bone marrow should be collected using sterile technique in a medically acceptable setting and according to standard operating procedures (AIII).HSCT transplant center personnel should keep accurate records of all HSCT received and the disposition of each sample obtained (381). These tracking records must be separate from patients' medical records (e.g., in a log book) so that this information is easily obtainable. Recorded information should include the donor identification number, name of procurement of distribution center supplying the HSCT, recipient-identifying information, name of recipient's physician, and dates of a) receipt by the HSCT center and b) either transplantation to the recipient or further distribution (381) (AIII). All centers for donation, transplantation, or collection of hematopoietic stem cells should keep records of donor screening and testing, and HSCT harvesting, processing, testing, cryopreservation, storage, and infusion or disposal of each aliquot of donated hematopoietic progenitor cells for >10 years after the date of implantation, transplantation, infusion, or transfer of the product (378) (AIII). However, if that date is not known, records should be retained >10 years after the product's distribution, disposition, or expiration, whichever is latest. 2ff7e9595c
Comments